Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

by Klement, Piroska , Gabdoulline, Razif , Wichmann, Martin , Büttner, Konstantin , Heuser, Michael , Ganser, Arnold , Thol, Felicitas , Eder, Matthias , Koenecke, Christian , Beutel, Gernot , Wienecke, Clara , Teich, Katrin , Stadler, Michael , Heida, Bennet , Venturini, Letizia , Schultze-Florey, Christian , Kandarp, Jyoti , Puppe, Wolfram

in Acute myeloid leukemia / Allografts / Bioinformatics / Biomarkers / Blood / Chemotherapy / Error correction & detection / Genes / Genetic testing / Graft versus host disease / Graft-versus-leukemia reaction / Hematopoietic stem cells / Leukemia / Lymphocytes / Multivariate analysis / Mutation / Next-generation sequencing / Patients / Remission / Signal transduction / Transplantation / Variables

2023

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

2023

Confirm

Do you wish to request the book?

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

2023

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

Klement, Piroska,

Gabdoulline, Razif,

Wichmann, Martin,

Büttner, Konstantin,

Heuser, Michael,

Ganser, Arnold,

Thol, Felicitas,

Eder, Matthias,

Koenecke, Christian,

Beutel, Gernot,

Wienecke, Clara,

Teich, Katrin,

Stadler, Michael,

Heida, Bennet,

Venturini, Letizia,

Schultze-Florey, Christian,

Kandarp, Jyoti,

Puppe, Wolfram

2023

Overview

Donor lymphocyte infusions (DLIs) can directly target leukemic cells through a graft-versus-leukemia effect and play a key role in the prevention and management of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Predictors of response to DLIs are not well established. We evaluated measurable residual disease (MRD) before, 30 and 90 days after DLI treatment as biomarkers of response. MRD was assessed by next-generation sequencing in 76 DLI-treated acute myeloid leukemia patients. MRD status before DLI treatment was independently prognostic for event-free survival (EFS, p < 0.001) and overall survival (OS, p < 0.001). Within 90 days of DLI treatment, 73% of MRD+ patients converted to MRD− and 32% of patients without remission achieved remission. MRD status 90 days after DLI treatment was independently prognostic for the cumulative incidence of relapse (CIR, p = 0.011) and relapse-free survival (RFS, p = 0.001), but not for OS. To evaluate the role of DLI treatment in MRD− patients, 23 MRD− patients who received DLIs were compared with a control cohort of 68 MRD− patients not receiving DLIs. RFS (p = 0.23) and OS (p = 0.48) were similar between the two cohorts. In conclusion, MRD is prognostic before (EFS, OS) and after (CIR, RFS) DLI treatment and may help in the selection of patients who benefit most from DLIs.

Share this book

Add to My Shelf

Publisher

MDPI AG,MDPI

Subject

Acute myeloid leukemia

/ Blood

/ Error correction & detection